XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.2

Revenue (Tables)

6 Months Ended

Jun. 30, 2021

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following table summarizes our revenue recognized in our consolidated condensed statements of operations:

			Three Months Ended June 30,												Six Months Ended June 30,
			2021						2020						2021						2020
Net product revenue			$	6,070.5					$	5,077.7					$	12,390.5					$	10,481.2
Collaboration and other revenue (1)			669.6						421.7						1,155.2						878.0
Revenue			$	6,740.1					$	5,499.4					$	13,545.7					$	11,359.2

(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $31.0 million and $73.9 million during the three and six months ended June 30, 2021, respectively, and $34.7 million and $70.0 million during the three and six months ended June 30, 2020, respectively.

The following table summarizes revenue by product for the three months ended June 30, 2021 and 2020:

			Three Months Ended June 30,
			2021												2020
			U.S.			Outside U.S.			Total						U.S.			Outside U.S.			Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®			$	1,147.6		$	388.0		$	1,535.6					$	952.5		$	277.2		$	1,229.8
Humalog® (1)			329.1			278.6			607.6						281.7			273.3			555.1
Humulin®			221.1			94.3			315.3						214.3			99.3			313.6
Jardiance (2)			194.4			162.1			356.5						145.1			116.9			262.0
Basaglar®			133.4			77.3			210.7						229.7			60.7			290.4
Other Diabetes			54.2			95.4			149.8						50.0			78.3			128.1
Total Diabetes			2,079.8			1,095.7			3,175.5						1,873.3			905.7			2,779.0
Oncology:
Alimta®			353.5			257.1			610.6						317.2			221.9			539.1
Verzenio®			209.7			131.6			341.3						141.7			66.9			208.6
Cyramza®			101.4			167.3			268.7						94.1			162.7			256.7
Erbitux®			135.8			11.2			147.0						115.8			13.7			129.5
Tyvyt®			—			105.0			105.0						—			64.1			64.1
Other Oncology			27.9			53.5			81.4						13.9			56.6			70.6
Total Oncology			828.3			725.7			1,554.0						682.7			585.9			1,268.6
Immunology:
Taltz®			399.8			169.3			569.1						289.2			106.0			395.2
Olumiant®			17.8			190.6			208.4						13.2			131.8			145.0
Other Immunology			4.8			3.2			7.9						8.1			—			8.1
Total Immunology			422.4			363.1			785.4						310.5			237.8			548.3
Neuroscience:
Cymbalta®			12.4			163.3			175.6						7.7			172.1			179.9
Emgality®			112.1			44.2			156.3						80.6			6.8			87.4
Zyprexa®			8.4			86.9			95.4						9.1			87.5			96.6
Other Neuroscience			33.8			51.1			84.9						6.6			52.1			58.6
Total Neuroscience			166.7			345.5			512.2						104.0			318.5			422.5
Other:
COVID-19 Antibodies (3)			83.4			65.7			148.9						—			—			—
Forteo®			122.8			95.6			218.4						119.6			133.0			252.7
Cialis®			(5.2)			286.3			281.0						23.4			107.3			130.7
Other			6.0			58.4			64.6						31.4			66.4			97.6
Total Other			207.0			506.0			712.9						174.4			306.7			481.0
Revenue			$	3,704.2		$	3,035.9		$	6,740.1					$	3,144.8		$	2,354.6		$	5,499.4

Numbers may not add due to rounding.

(1) Humalog revenue includes insulin lispro.

(2) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.

(3) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations (EUAs).

The following table summarizes revenue by product for the six months ended June 30, 2021 and 2020:

			Six Months Ended June 30,
			2021												2020
			U.S.			Outside U.S.			Total						U.S.			Outside U.S.			Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity			$	2,264.3		$	723.7		$	2,988.1					$	1,882.0		$	577.1		$	2,459.1
Humalog (1)			661.7			562.9			1,224.6						680.3			570.5			1,250.8
Humulin			440.1			196.9			637.0						428.4			200.8			629.3
Jardiance (2)			345.6			322.9			668.5						289.7			239.8			529.5
Basaglar			308.6			148.7			457.3						460.1			134.0			594.1
Other Diabetes			120.7			190.4			311.1						124.0			161.2			285.1
Total Diabetes			4,141.0			2,145.5			6,286.6						3,864.5			1,883.4			5,747.9
Oncology:
Alimta			614.6			554.9			1,169.6						641.5			457.7			1,099.2
Verzenio			382.5			227.8			610.3						271.1			125.6			396.7
Cyramza			181.5			327.7			509.2						183.2			312.5			495.7
Erbitux			243.7			25.7			269.4						233.7			26.7			260.3
Tyvyt			—			214.6			214.6						—			121.5			121.5
Other Oncology			48.5			104.7			153.2						11.1			85.5			96.7
Total Oncology			1,470.8			1,455.4			2,926.3						1,340.6			1,129.5			2,470.1
Immunology:
Taltz			649.4			322.9			972.4						616.7			222.0			838.7
Olumiant			42.5			359.7			402.2						24.5			260.2			284.7
Other Immunology			15.2			9.6			24.7						10.7			—			10.7
Total Immunology			707.1			692.2			1,399.3						651.9			482.2			1,134.1
Neuroscience:
Cymbalta			23.3			328.9			352.3						19.3			370.9			390.3
Emgality			213.6			62.2			275.7						147.9			13.6			161.5
Zyprexa			15.3			175.8			191.1						20.3			174.7			195.0
Other Neuroscience			56.2			102.3			158.5						26.7			112.5			139.2
Total Neuroscience			308.4			669.2			977.6						214.2			671.7			886.0
Other:
COVID-19 Antibodies (3)			734.0			225.1			959.1						—			—			—
Forteo			220.5			196.4			416.9						242.2			282.9			525.0
Cialis			3.4			404.4			407.8						49.5			274.3			323.8
Other			60.2			111.9			172.1						110.7			161.5			272.3
Total Other			1,018.1			937.8			1,955.9						402.4			718.7			1,121.1
Revenue			$	7,645.5		$	5,900.2		$	13,545.7					$	6,473.6		$	4,885.6		$	11,359.2

Numbers may not add due to rounding.

(1) Humalog revenue includes insulin lispro.

(2) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.

(3) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.

The following table summarizes revenue by geographical area:

			Three Months Ended June 30,												Six Months Ended June 30,
			2021						2020						2021						2020
Revenue—to unaffiliated customers (1):
U.S.			$	3,704.2					$	3,144.8					$	7,645.5					$	6,473.6
Europe			1,209.8						873.0						2,531.0						1,934.1
Japan			665.4						666.7						1,237.2						1,259.0
China			522.5						239.8						884.7						507.1
Other foreign countries			638.1						575.2						1,247.3						1,185.5
Revenue			$	6,740.1					$	5,499.4					$	13,545.7					$	11,359.2

Numbers may not add due to rounding.

(1) Revenue is attributed to the countries based on the location of the customer.

Schedule of amounts recorded for contract liabilities

The following table summarizes contract liability balances:

			June 30, 2021						December 31, 2020
Contract liabilities			$	270.9					$	276.8

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration